Investment Thesis
Evofem Biosciences exhibits severe financial distress with negative stockholders' equity of -$74.3M, indicating the company is technically insolvent. Despite modest revenue growth of 4.2% YoY and a 16.7% operating margin, negative operating cash flow of -$2.0M and critically low liquidity (0.18x current ratio) with only $578K in cash create an imminent solvency crisis. The company's ability to continue operations is highly questionable without immediate capital restructuring or substantial external financing.
Strengths
- Positive net income of $391K with 42.7% YoY improvement showing path to profitability
- Modest revenue growth of 4.2% YoY indicating stable top-line performance
- Relatively strong operating margin of 16.7% demonstrating operational efficiency
Risks
- Negative stockholders' equity of -$74.3M indicating technical insolvency and balance sheet distress
- Critical liquidity crisis with current ratio of 0.18x and only $578K cash against $89.7M total liabilities
- Severely negative operating cash flow of -$2.0M suggesting the company is burning cash and cannot sustain operations without external funding
- Negative free cash flow of -$2.0M with -9.9% FCF margin indicating unsustainable business model
- High leverage with $2.8M long-term debt and weak interest coverage of 1.4x
- Zero insider Form 4 filings in last 90 days indicating lack of insider confidence
Key Metrics to Watch
- Operating cash flow trajectory and path to positive free cash flow
- Cash balance and runway given current burn rate
- Stockholders' equity recovery and balance sheet restructuring efforts
- Revenue growth acceleration beyond 4.2% to support profitability scaling
Financial Metrics
Revenue
20.2M
Net Income
391.0K
EPS (Diluted)
$0.00
Free Cash Flow
-2.0M
Total Assets
20.3M
Cash
578.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
16.7%
Net Margin
1.9%
ROE
N/A
ROA
1.9%
FCF Margin
-9.9%
Balance Sheet & Liquidity
Current Ratio
0.18x
Quick Ratio
0.17x
Debt/Equity
N/A
Debt/Assets
442.5%
Interest Coverage
1.43x
Long-term Debt
2.8M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-24T14:58:11.971059 |
Data as of: 2025-12-31 |
Powered by Claude AI